Xoma | XOMA - Gross Profit On Sales


Xoma reported 992K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agenus USD 34.2M 4.61M Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
aTyr Pharma USD 190K 15.57M Sep/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Celldex Therapeutics USD 121K 609K Dec/2025
Curis USD 1.14M 8.86M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 21K 2.39M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Xoma 992K 846K Jun/2024